Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Soluble fibrin is a blood plasma protein arising from the enzymatic cleavage of fibrinogen by thrombin; it is composed of monomeric or small oligomeric fibrin units lacking fibrinopeptides, which can later self-assemble to form insoluble, cross-linked fibrin clots under physiological or pathological conditions. Soluble fibrin exists transiently in the bloodstream and serves as a marker of ongoing coagulation activation and clot formation. Its measurement has applications in clinical diagnosis of thrombotic disorders, and its presence is associated with both normal hemostasis and pathological thrombosis. Soluble fibrin is not a classical drug target but is indirectly affected by drugs that act on the coagulation cascade, such as anticoagulants. Elevated levels are concerning in cardiovascular and inflammatory disease states, and it is used as a biomarker rather than a direct therapeutic target.
Drugs affecting soluble fibrin act by inhibiting thrombin, interfering with fibrin polymerization, or promoting fibrinolysis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Soluble fibrin (SF).